While a comprehensive review of 93 studies revealed the diagnostic value of radiomics in the differentiation of RCC [29], another systematic review including 331 patients concluded that PSMA-targeted PET/CT imaging was associated with enhanced detection in ccRCC and could be utilized as a biomarker of disease aggressiveness [30]. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.